Days after getting acquired by Biogen, Human Immunology Biosciences revealed Phase 2 data that helped seal the deal.
In the trial, which looked at the anti-CD38 antibody felzartamab’s potential to treat IgA nephropathy, patients saw an average reduction in protein urine levels of up to 50% after two years, HI-Bio said Friday. Patients received nine doses of the drug over the course of 24 weeks and saw eGFR levels stabilize, indicating normal kidney function.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.